Quick Facts
Adaptam Therapeutics has secured €3 million in a pre-seed funding round to advance its cancer immunotherapy pipeline.
The round was led by Criteria Bio Ventures, whose partners Salvatore Cappadona and Pablo Cironi joined Adaptam’s board.
Adaptam will use the funding to push its antibody-based programmes—including antibody-drug conjugates (ADCs) and bispecific antibodies—into preclinical development across multiple oncology indications.
The company is targeting immunosuppressive myeloid cells in the tumour microenvironment, such as tumour-associated macrophages (TAMs), which are a major barrier to effective immunotherapies for solid tumours.
Adaptam is a spin-out from CIC bioGUNE and is based in San Sebastián and Barcelona, Spain.
The scientific foundation of the company rests on glycobiology-driven discovery—specifically glyco-immune checkpoints expressed on myeloid cells—which represents a novel therapeutic angle in immuno-oncology.
Adaptam plans to follow this seed round with an IND-enabling study phase as it works to bring its first candidates closer to clinical evaluation.
Investor activity in Europe’s immuno-oncology sector remains strong in 2025, with Adaptam’s raise joining other biotech funding announcements in the region.
This funding milestone enables Adaptam to build its scientific and operational capabilities and prepare for further growth as a challenger in the immunotherapy space.